Clinical trials: Multiple Myeloma (MM)
Multiple Myeloma (MM)
Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma
The purpose of this study is to see if researchers could get the same good results with less toxicity by using this new approach.
- Trial name
- NCT01919086
- Testing
- Bortezomib, Dexamethasone, Lenalidomide
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma (MM)
An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma
To characterize the safety profile of acalabrutinib with and without dexamethasone in subjects with relapsed or refractory Multiple Myeloma (MM)
- Trial name
- NCT02211014
- Testing
- acalabrutinib
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 27 people
- Sponsor
- Acerta Pharma BV